Improving Survival in Patients with High-Risk and Metastatic Melanoma

Cancer Statistics, 2003

2003 • 3,302 citations

Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells

1998 • 2,916 citations

Final Version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma

2001 • 2,658 citations

Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic Cancer

1985 • 2,616 citations

Interleukin-2: Inception, Impact, and Implications

1988 • 2,166 citations

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

1996 • 2,073 citations

High-Dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993

1999 • 1,967 citations

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

1998 • 1,826 citations

Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity

1995 • 1,097 citations

High- and Low-Dose Interferon Alfa-2b in High-Risk Melanoma: First Analysis of Intergroup Trial E1690/S9111/C9190

2000 • 923 citations

High-Dose Interferon Alfa-2b Significantly Prolongs Relapse-Free and Overall Survival Compared With the GM2-KLH/QS-21 Vaccine in Patients With Resected Stage IIB-III Melanoma: Results of Intergroup Trial E1694/S9512/C509801

2001 • 905 citations

Phase III Multicenter Randomized Trial of the Dartmouth Regimen Versus Dacarbazine in Patients With Metastatic Melanoma

1999 • 756 citations

Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2.

1985 • 737 citations

A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E.

1992 • 694 citations

Prospective Randomized Trial of High-Dose Interleukin-2 Alone or in Conjunction With Lymphokine-Activated Killer Cells for the Treatment of Patients With Advanced Cancer

1993 • 639 citations

Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes.

1994 • 584 citations

Tumor-specific cytolysis by lymphocytes infiltrating human melanomas.

1989 • 511 citations

Randomised trial of interferon α-2a as adjuvant therapy in resected primary melanoma thicker than 1·5 mm without clinically detectable node metastases

1998 • 437 citations

Two tyrosinase nonapeptides recognized on HLA‐A2 melanomas by autologous cytolytic T lymphocytes

1994 • 421 citations

Prolongation of Survival in Metastatic Melanoma After Active Specific Immunotherapy With a New Polyvalent Melanoma Vaccine

1992 • 410 citations

Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer.

1989 • 383 citations

A peptide encoded by human gene MAGE‐3 and presented by HLA‐A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE‐3

1994 • 379 citations

Sequential Biochemotherapy Versus Chemotherapy for Metastatic Melanoma: Results From a Phase III Randomized Trial

2002 • 378 citations

Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group.

1998 • 366 citations

Prospective Randomized Trial of the Treatment of Patients With Metastatic Melanoma Using Chemotherapy With Cisplatin, Dacarbazine, and Tamoxifen Alone or in Combination With Interleukin-2 and Interferon Alfa-2b

1999 • 318 citations

Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study.

1998 • 309 citations

Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic results in 64 patients.

1990 • 300 citations

Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma.

1998 • 298 citations

Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A.

1997 • 286 citations

Adjuvant Therapy of Stage III and IV Malignant Melanoma Using Granulocyte-Macrophage Colony-Stimulating Factor

2000 • 271 citations

Sequential chemoimmunotherapy in the treatment of metastatic melanoma.

1992 • 258 citations

Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma.

1995 • 253 citations

Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial

2001 • 250 citations

Active specific immunotherapy for melanoma: phase I trial of allogeneic lysates and a novel adjuvant.

1988 • 239 citations

Induction of apoptosis in NK cells by monocyte-derived reactive oxygen metabolites.

1996 • 215 citations

Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study.

1996 • 206 citations

Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients.

1998 • 206 citations

Improved results with the addition of interferon alfa-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma.

1991 • 200 citations

Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group.

1997 • 197 citations

Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma.

1993 • 181 citations

Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-α

1996 • 176 citations

Results From a Randomized Phase III Study Comparing Combined Treatment With Histamine Dihydrochloride Plus Interleukin-2 Versus Interleukin-2 Alone in Patients With Metastatic Melanoma

2002 • 166 citations

Antigen-specific tumor vaccines. Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy.

1996 • 161 citations

Synergistic antitumor effects of combination immunotherapy with recombinant interleukin-2 and a recombinant hybrid alpha-interferon in the treatment of established murine hepatic metastases.

1988 • 153 citations

Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alfa-2a for metastatic melanoma.

1993 • 147 citations

Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma.

1994 • 131 citations

Autologous hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases.

1997 • 128 citations

A phase III randomized, doúble-blind, multiinstitutional trial of vaccinia melanoma oncolysate-active specific immunotherapy for patients with stage II melanoma

1995 • 121 citations

Why Do So Many Cancer Patients Fail to Respond to Interferon Therapy?

1996 • 101 citations

Concomitant administration of recombinant human interleukin-2 and recombinant interferon alpha-2A in cancer patients: a phase I study.

1989 • 96 citations

Relationship between immune response to melanoma vaccine immunization and clinical outcome in stage II malignant melanoma

1992 • 89 citations

The role of adjuvant therapy in melanoma management

1995 • 89 citations

Combination therapy with interferon alfa-2a and interleukin-2 for the treatment of metastatic cancer.

1995 • 89 citations

Economic analysis of adjuvant interferon alfa-2b in high-risk melanoma based on projections from Eastern Cooperative Oncology Group 1684.

1997 • 89 citations

A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alpha-2B in patients with metastatic melanoma.

2000 • 82 citations

Results From a Randomized Phase III Study Comparing Combined Treatment With Histamine Dihydrochloride Plus Interleukin-2 Versus Interleukin-2 Alone in Patients With Metastatic Melanoma

2002 • 75 citations

Chemoimmunotherapy of advanced malignant melanoma: sequential administration of subcutaneous interleukin-2 and interferon-α after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen

1995 • 71 citations

Histamine H2-receptor-mediated regulation of human natural killer cell activity.

1986 • 69 citations

Recombinant interferon alfa-2a in advanced malignant melanoma. a phase i-ii study in combination with dtic

1987 • 67 citations

Development and results of biochemotherapy in metastatic melanoma: the University of Texas M.D. Anderson Cancer Center experience.

1997 • 64 citations

Outpatient Biochemotherapy With Interleukin-2 and Interferon Alfa-2b in Patients With Metastatic Malignant Melanoma: Results of Two Phase II Cytokine Working Group Trials

2001 • 58 citations

Phase II trials of recombinant leukocyte A interferon in disseminated malignant melanoma: results in 96 patients.

1986 • 55 citations

Adjuvant therapy for melanoma

1997 • 54 citations

Active immunotherapy with viral lysates of micrometastases following surgical removal of high risk melanoma

1992 • 47 citations

Adjuvant therapy of melanoma

1998 • 47 citations

Randomized trial of adjuvant therapy for "high risk" primary malignant melanoma.

1978 • 47 citations

A retrospective cost-effectiveness analysis of interferon as adjuvant therapy in high-risk resected cutaneous melanoma

1997 • 36 citations

Updated analysis of an outpatient chemoimmunotherapy regimen for treating metastatic melanoma.

1997 • 28 citations

Outpatient chemoimmunotherapy for the treatment of metastatic melanoma.

1997 • 27 citations

Phase I trial of continuous infusion recombinant interleukin-2 and intermittent recombinant interferon-alpha 2a: clinical effects.

1990 • 21 citations

Final report of a phase II study of interleukin 2 and interferon α in patients with metastatic melanoma

1995 • 20 citations

Dacarbazine (DTIC), human recombinant interferon alpha 2a (Roferon) and 5-fluorouracil for disseminated malignant melanoma

1992 • 18 citations

A randomised trial of vindesine plus interferon-α2b compared with interferon-α2b or vindesine alone in the treatment of advanced malignant melanoma

1994 • 14 citations

Molecular Diagnosis and Treatment of Melanoma

1998 • 8 citations

Dose escalation of dacarbazine combined with interferon alpha-2a, G-CSF and ondansetron in patients with metastatic melanoma.

1994 • 6 citations

American Society of Clinical Oncology - 37th Annual Meeting. Highlights of oral and poster sessions. 12-15 May 2001, San Francisco, CA, USA.

2001 • 2 citations